Building a Global Platform for a Breakthrough Cancer Therapy
Strategic Comms · Rebrand · Content · PR · Investor Relations
What we delivered
Full rebrand — identity, messaging, and digital presence rebuilt from the ground up
Investor-grade content strategy and PR program launched
Ongoing strategic comms partnership established
The Challenge
Alloplex had world-class science but lacked the digital platform and communications infrastructure to attract investors and partners. The website didn’t reflect the strength of the IP or the calibre of the team. In competitive biotech, first impressions determine whether capital conversations begin.
What They Built
A full rebrand gave Alloplex the platform its science deserved — positioning, messaging architecture, visual identity, and an investor-facing website built to open conversations. A content and PR strategy placed the company in front of life sciences investors, clinical collaborators, and biotech media. Social media and investor relations programs sustained momentum between milestones, keeping Alloplex visible and credible through every stage of development.
The Result
Alloplex now presents as a credible, professional global biotech platform. The new digital presence supports capital-raising conversations and positions the company in line with its genuine scientific ambition.